Business strategy
Vision
Our vision is to be recognised as a global leader in providing innovative medicines that transform the lives of people with rare and debilitating diseases.
Strategy
Our strategy has four strategic business priorities.
Lead in Haematology
We will continue to be a leader in haematology by increasing access to our extended half-life factor replacement medicines and bringing our medicines to more countries.
Grow Immunology and Specialty Care
We see potential for growth in Immunology and Specialty Care and aim to maximise value to patients and the company through the existing medicines in new countries and/or new indications.
Go global
Expanded access to treatment through geographical expansion is a key element of our commitment to patients. Our ambition is to reach more people in more countries with novel and transformative medicines in areas of high unmet medical need.
Capture the value of the pipeline
We are concentrating on mid and late stage opportunities that help address unmet medical needs and have significant market potential in the niches they serve. Read more about our pipeline.
Our sustainability strategy is integrated into the business and is based on two priorities – maintaining our commitment to patients and always acting responsibly. Read more about our sustainability priorities.